查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
前列腺癌治疗药物市场-全球行业规模、份额、趋势、机会、预测：按治疗（激素疗法、化学疗法、免疫疗法、趋势疗法、其他）、最终用户、竞争对手（2018-）2028）
市场调查报告书
商品编码
1244148

前列腺癌治疗药物市场-全球行业规模、份额、趋势、机会、预测：按治疗（激素疗法、化学疗法、免疫疗法、趋势疗法、其他）、最终用户、竞争对手（2018-）2028）

Prostate Cancer Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Others), By End User
出版日期: | 出版商: TechSci Research | 英文 111 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球前列腺癌药物市场预计到 2028 年将经历令人瞩目的增长。

男性前列腺的异常细胞生长和肥大被称为前列腺癌。 总体而言，前列腺癌是男性第 10 大死因和第 6 大死因。 前列腺癌的治疗包括手术、激素疗法、放射疗法、化学疗法和生物疗法。 前列腺癌、小细胞癌和良性前列腺增生症等诊断和治疗用于前列腺癌的治疗和管理。

不断增长的老年人口

前列腺癌是美国男性最常见的癌症，不包括非黑色素瘤皮肤癌。 它也是包括西班牙裔在内的所有种族男性癌症死亡的主要原因之一。 每 10 名 65 岁以上的男性中就有 6 名患有此病，而在 40 岁以下的男性中则很少见。 前列腺癌是美国男性中仅次于肺癌的第二大常见癌症。 美国的前列腺癌新病例预计将从 2009 年的 192,280 例增加到 2022 年的约 268,490 例。 此外，据估计，到 2022 年美国将有大约 34,500 名男性死于前列腺癌，这将增加美国对前列腺癌药物的需求。

推出新的治疗药物

由于诊断技术的进步，前列腺癌的诊断已经发生了变化。 监测 PSA 水平有助于检测前列腺癌。 几种新的细胞毒性药物、激素疗法和其他抗前列腺特异性膜抗原疗法的 II 期和 III 期试验正在进行中。 梅奥医学教育和研究基金会 (MFMER) 表示，激素疗法和抗细胞毒性 T 淋巴细胞相关抗原 (CTLA) 疗法的结合可以诱导针对前列腺肿瘤的靶向免疫反应。 因此，治疗创新有望推动全球前列腺癌治疗市场的增长。 此外，主要市场参与者的产品发布和药物创新预计将推动全球前列腺癌治疗市场的增长。

激素治疗的副作用

前列腺癌是一种慢性病，治疗週期长。 激素治疗的副作用包括勃起功能障碍、潮热、骨密度下降、骨折、肌肉质量和力量下降、血脂变化、胰岛素抵抗、体重增加、情绪波动、疲劳、乳房组织生长（女性化）。 ）， ETC。 因此，长期接受激素治疗会影响个人的日常生活并增加出现健康问题的风险。

此外，副作用因人而异，用于治疗癌症的剂量也是如此。 因此，癌症治疗的副作用预计会阻碍市场增长。

市场细分

前列腺癌治疗药物的全球市场根据治疗方法和最终用户进行细分。 基于疗法，市场分为激素疗法、化学疗法、免疫疗法和靶向疗法。 激素疗法进一步分为黄体生成素释放激素 (LHRH) 拮抗剂、激素释放激素 (LHRH) 激动剂和抗雄激素。 化疗领域分为taxotere和jevtana。 免疫疗法包括 Provenge，靶向疗法包括 Xofigo 等。 最终用户部分进一步细分为医院、专科诊所、门诊手术中心等。

近期发展

  • 2022 年 3 月，BioPharma 宣布获得用于成年晚期前列腺癌患者的 42 毫克注射乳剂“CAMC□□EVI（亮丙瑞林）”的许可。 该业务还提供对 AccordConnects 的访问，AccordConnects 是用于 Camcevi 库存管理的移动应用程序。

营销人员

Johnson &Johnson;Services Inc;Astellas Pharma Inc;Eli Lilly and Company;Sanofi;Ipsen Pharma;Bayer AG;AstraZeneca;Valeant Pharmaceuticals International, Inc;Merck &Co., Inc; 它是製药市场的主要参与者.

报告范围

本报告将全球前列腺癌治疗市场分为以下几类，以及下面详述的行业趋势：

前列腺癌药物市场，按治疗：

  • 激素疗法
    • 促黄体激素释放激素 (LHRH) 拮抗剂
    • 促黄体激素释放激素 (LHRH) 激动剂
    • 抗雄激素
  • 化疗
    • 泰索帝
    • 杰夫塔纳
  • 免疫疗法
    • 普罗旺斯
  • 靶向治疗
    • X 福伊戈
  • 其他

前列腺癌药物市场，按最终用户分类：

  • 医院
  • 专科诊所
  • 门诊手术中心
  • 其他

按地区划分的前列腺癌药物市场：

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
  • 中东和非洲
    • 阿联酋
    • 南阿拉伯
    • 沙特阿拉伯
    • 土耳其人
    • 埃及

竞争格局

公司概况：对全球前列腺癌治疗市场主要参与者的深入分析。

可自定义：

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

  • 对其他市场公司（最多 5 家公司）进行深入分析和概况分析。

内容

第一章服务概述

  • 市场定义
  • 市场范围
    • 目标市场
    • 研究目标年份
    • 主要市场细分

第二章研究方法论

  • 调查目的
  • 基线调查方法
  • 主要行业合作伙伴
  • 主要协会和次要信息
  • 调查方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章执行摘要

  • 市场概览
  • 主要市场细分概述
  • 主要市场参与者概览
  • 主要地区/国家概览
  • 市场驱动因素、挑战和趋势概述

第 4 章 VOC（客户之声）

第五章全球前列腺癌药物市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按治疗方法（激素疗法、化学疗法、免疫疗法、靶向疗法等）
    • 最终用户（医院、肿瘤诊所、门诊手术中心等）
    • 按地区
    • 按公司分类（2022 年）
  • 市场地图
    • 通过治疗
    • 最终用户

第六章北美前列腺癌药物市场前景

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按治疗方法（激素疗法、化学疗法、免疫疗法、靶向疗法等）
    • 最终用户（医院、肿瘤诊所、门诊手术中心等）
    • 按国家
  • 北美：国家/地区分析
    • 美国前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 加拿大前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 墨西哥前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户

第七章欧洲前列腺癌药物市场前景

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按治疗方法（激素疗法、化学疗法、免疫疗法、靶向疗法等）
    • 最终用户（医院、肿瘤诊所、门诊手术中心等）
    • 按国家
  • 欧洲：国家分析
    • 法国前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 德国前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 英国前列腺癌药物市场的前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 意大利前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 西班牙前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户

第8章亚太地区前列腺癌药物市场前景

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按治疗方法（激素疗法、化学疗法、免疫疗法、靶向疗法等）
    • 最终用户（医院、肿瘤诊所、门诊手术中心等）
    • 按国家
  • 亚太地区：国家/地区分析
    • 中国前列腺癌药物市场展望
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 日本前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 印度前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 韩国前列腺癌药物市场的前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 澳大利亚前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户

第9章南美前列腺癌药物市场前景

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按治疗方法（激素疗法、化学疗法、免疫疗法、靶向疗法等）
    • 最终用户（医院、肿瘤诊所、门诊手术中心等）
    • 按国家
  • 南美洲：：国家分析
    • 巴西前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 阿根廷前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 哥伦比亚前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户

第 10 章中东和非洲前列腺癌药物市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按治疗方法（激素疗法、化学疗法、免疫疗法、靶向疗法等）
    • 最终用户（医院、肿瘤诊所、门诊手术中心等）
    • 按国家
  • MEA：国家分析
    • 阿联酋前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 沙特阿拉伯的前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 沙特阿拉伯的前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 土耳其前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户
    • 埃及前列腺癌药物市场前景
      • 市场规模和预测
        • 按价值观
      • 市场份额和预测
        • 通过治疗
        • 最终用户

第 11 章市场动态

  • 司机
    • 前列腺癌的患病率增加
    • 采用新的筛查和诊断技术
    • 研发快速增长
  • 做
    • 昂贵的癌症治疗费用
    • 关于激素疗法的副作用

第12章市场趋势与发展

  • 产品发布
  • M&A（併购）
  • 技术进步

第13章临床试验分析

第 14 章全球前列腺癌药物市场：SWOT 分析

第15章竞争格局

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials（In Case of Listed Companies）
  • Key Personnel
  • SWOT Analysis
    • Johnson & Johnson Services, Inc.
    • Astellas Pharma Inc.
    • Eli Lilly and Company
    • Sanofi S.A.
    • Ipsen Pharma
    • Bayer AG
    • AstraZeneca Plc
    • Valeant Pharmaceuticals International, Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.

第16章 战略建议

简介目录
Product Code: 14698

Global prostate cancer therapeutics market is anticipated to grow at an impressive rate through 2028. The multiplication and abnormal enlargement of the prostate gland's aberrant cells in men are known as prostate cancer. Overall, the tenth leading cause of mortality and the sixth major cause of death in men is prostate cancer. Treatments for prostate cancer include surgery, hormone therapy, radiation, chemotherapy, and biological therapy. Prostatic adenocarcinoma, small cell carcinoma, benign prostatic hyperplasia, and other diagnoses and treatments are used to treat and manage prostate cancer.

An aging population, the sedentary lifestyle of those in industrialized nations, and the early start of urological problems are all factors that contribute to the prevalence of prostate cancer, globally. The rise in the geriatric population, upsurge in generic medicines, increasing awareness among people concerning the treatment of prostate cancer, availability of new prostate cancer treatments, and strong emerging pipeline drugs are the factors expected to accelerate the growth of the market. Furthermore, the rise in research and development activities and innovation in drugs is anticipated to boost the growth of the global prostate cancer therapeutics market.

Increasing Elderly Population

Prostate cancer is the most prevalent cancer among men in the US, aside from non-melanoma skin cancer. Additionally, it is one of the major causes of cancer death in males of all races including those of Hispanic ancestry. It is diagnosed in about 6 out of 10 men who are 65 and rare in men under 40. Prostate cancer is the second most common cancer among American males, after lung cancer. In the United States, it was predicted that about 268,490 new cases of prostate cancer were reported in 2022, up from 192,280 new cases in 2009. Moreover, it was estimated that, in 2022, around 34,500 men would die of prostate cancer in the U.S. This, in turn, increased the demand for prostate cancer therapeutics in the US.

Launch of Emerging Novel Therapies

The diagnosis of prostate cancer has transformed owing to advanced diagnostic technologies. The detection of prostate cancer has been assisted by the monitoring of PSA levels. Phase II and phase III trials are underway for several novel cytotoxic medications, hormonal treatments, and other anti-prostate-specific membrane antigen therapies. The Mayo Foundation for Medical Education and Research (MFMER) states that a targeted immune response can be induced against prostate tumors using a combination of hormonal and anti-cytotoxic T-lymphocyte-associated antigen (CTLA) treatment approaches. Hence, innovation in therapies is expected to enhance the growth of the global Prostate Cancer Therapeutics Market. Further, product launches and innovation in medicines by key market players have anticipated booming the growth of the global Prostate Cancer Therapeutics Market.

Side Effects of Hormonal Treatment

Prostate Cancer is a chronic disease with lengthy treatments. The side effects of hormonal treatment include erectile dysfunction, hot flashes, loss of bone density, bone fractures, loss of muscle mass and physical strength, changes in blood lipids, insulin resistance, weight gain, mood swings, fatigue, and the growth of breast tissue (gynecomastia). Hence, long exposure to hormonal treatment affects individuals' daily life and increases the risk of health problems.

Moreover, side effects vary from person to person and the dose used to treat cancer. Hence, the side effects of cancer treatment are projected to hamper the growth of the market.

Market Segmentation

The global Prostate Cancer Therapeutics Market is segmented based on treatment and end user. Based on treatment, the market is categorized into hormonal therapy, chemotherapy, immunotherapy, and target therapy. Hormonal therapy is further divided into Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists, Hormone-Releasing Hormone (LHRH) Agonists, and Anti-Androgen. The chemotherapy therapy segment is bifurcated into Taxotere and Jevtana. The immunotherapy segment includes Provenge and targeted therapy includes Xofigo and Others. The end-user segment is further segmented into Hospitals, Specialized Clinics, Ambulatory Surgical Centers, and Others.

Recent Developments

  • The introduction of CAMCEVI (leuprolide), a 42mg injection emulsion for the treatment of adults with advanced prostate cancer was announced by BioPharma in March 2022. The business also provides access to the AccordConnects mobile application for the administration of Camcevi inventories.

Market players

Johnson & Johnson; Services Inc.; Astellas Pharma Inc.; Eli Lilly and Company; Sanofi; Ipsen Pharma; Bayer AG; AstraZeneca; Valeant Pharmaceuticals International, Inc.; Merck & Co., Inc.; Pfizer Inc are the major players operating in the global prostate cancer therapeutics market.

Report Scope:

In this report, the global Prostate Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prostate Cancer Therapeutics Market, By Treatment:

  • Hormonal Therapy
    • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
    • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
    • Anti-Androgen
  • Chemotherapy
    • Taxotere
    • Jevtana
  • Immunotherapy
    • Provenge
  • Targeted Therapy
    • Xofigo
  • Others

Prostate Cancer Therapeutics Market, By End User:

  • Hospitals
  • Specialized Clinics
  • Ambulatory Surgical centers
  • Others

Prostate Cancer Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • UAE
    • South Arabia
    • Saudi Africa
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prostate Cancer Therapeutics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Prostate Cancer Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
      • 5.2.1.1. Hormonal Therapy
        • 5.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • 5.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • 5.2.1.1.3. Anti-Androgen
      • 5.2.1.2. Chemotherapy
        • 5.2.1.2.1. Taxotere
        • 5.2.1.2.2. Jevtana
      • 5.2.1.3. Immunotherapy
        • 5.2.1.3.1. Provenge
      • 5.2.1.4. Target Therapy
        • 5.2.1.4.1. Xofigo
      • 5.2.1.5. Others
    • 5.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Treatment
    • 5.3.2. By End User

6. North America Prostate Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
      • 6.2.1.1. Hormonal Therapy
        • 6.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • 6.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • 6.2.1.1.3. Anti-Androgen
      • 6.2.1.2. Chemotherapy
        • 6.2.1.2.1. Taxotere
        • 6.2.1.2.2. Jevtana
      • 6.2.1.3. Immunotherapy
        • 6.2.1.3.1. Provenge
      • 6.2.1.4. Target Therapy
        • 6.2.1.4.1. Xofigo
      • 6.2.1.5. Others
    • 6.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Prostate Cancer Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Prostate Cancer Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Prostate Cancer Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By End User

7. Europe Prostate Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
      • 7.2.1.1. Hormonal Therapy
        • 7.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • 7.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • 7.2.1.1.3. Anti-Androgen
      • 7.2.1.2. Chemotherapy
        • 7.2.1.2.1. Taxotere
        • 7.2.1.2.2. Jevtana
      • 7.2.1.3. Immunotherapy
        • 7.2.1.3.1. Provenge
      • 7.2.1.4. Target Therapy
        • 7.2.1.4.1. Xofigo
      • 7.2.1.5. Others
    • 7.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Prostate Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By End User
    • 7.3.2. Germany Prostate Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Prostate Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Prostate Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Prostate Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By End User

8. Asia-Pacific Prostate Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
      • 8.2.1.1. Hormonal Therapy
        • 8.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • 8.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • 8.2.1.1.3. Anti-Androgen
      • 8.2.1.2. Chemotherapy
        • 8.2.1.2.1. Taxotere
        • 8.2.1.2.2. Jevtana
      • 8.2.1.3. Immunotherapy
        • 8.2.1.3.1. Provenge
      • 8.2.1.4. Target Therapy
        • 8.2.1.4.1. Xofigo
      • 8.2.1.5. Others
    • 8.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Prostate Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By End User
    • 8.3.2. Japan Prostate Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By End User
    • 8.3.3. India Prostate Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Prostate Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Prostate Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By End User

9. South America Prostate Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
      • 9.2.1.1. Hormonal Therapy
        • 9.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • 9.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • 9.2.1.1.3. Anti-Androgen
      • 9.2.1.2. Chemotherapy
        • 9.2.1.2.1. Taxotere
        • 9.2.1.2.2. Jevtana
      • 9.2.1.3. Immunotherapy
        • 9.2.1.3.1. Provenge
      • 9.2.1.4. Target Therapy
        • 9.2.1.4.1. Xofigo
      • 9.2.1.5. Others
    • 9.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Prostate Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Prostate Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Prostate Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By End User

10. Middle East and Africa Prostate Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
      • 10.2.1.1. Hormonal Therapy
        • 10.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • 10.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • 10.2.1.1.3. Anti-Androgen
      • 10.2.1.2. Chemotherapy
        • 10.2.1.2.1. Taxotere
        • 10.2.1.2.2. Jevtana
      • 10.2.1.3. Immunotherapy
        • 10.2.1.3.1. Provenge
      • 10.2.1.4. Target Therapy
        • 10.2.1.4.1. Xofigo
      • 10.2.1.5. Others
    • 10.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Prostate Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Prostate Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By End User
    • 10.3.3. Saudi Africa Prostate Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By End User
    • 10.3.4. Turkey Prostate Cancer Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Treatment
        • 10.3.4.2.2. By End User
    • 10.3.5. Egypt Prostate Cancer Therapeutics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Treatment
        • 10.3.5.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
    • 11.1.1. Increasing Prevalence of Prostate Cancer.
    • 11.1.2. Adoption of Novel Screening and Diagnostic Technologies
    • 11.1.3. Surge in Research and Development
  • 11.2. Challenges
    • 11.2.1. High Cost of Cancer Treatment
    • 11.2.2. Side Effects of Hormonal Treatment

12. Market Trends & Developments

  • 12.1. Product Launches
  • 12.2. Mergers & Acquisitions
  • 12.3. Technological Advancements

13. Clinical Trial Analysis

14. Global Prostate Cancer Therapeutics Market: SWOT Analysis

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Financials (In Case of Listed Companies)
  • 15.5. Key Personnel
  • 15.6. SWOT Analysis
    • 15.6.1. Johnson & Johnson Services, Inc.
    • 15.6.2. Astellas Pharma Inc.
    • 15.6.3. Eli Lilly and Company
    • 15.6.4. Sanofi S.A.
    • 15.6.5. Ipsen Pharma
    • 15.6.6. Bayer AG
    • 15.6.7. AstraZeneca Plc
    • 15.6.8. Valeant Pharmaceuticals International, Inc.
    • 15.6.9. Merck & Co., Inc.
    • 15.6.10. Pfizer Inc.

16. Strategic Recommendations